Kenji Kishimoto1, Ryoji Kobayashi2, Daiki Hori2, Satoru Matsushima2, Masato Yanagi2, Hirozumi Sano2, Daisuke Suzuki2, Kunihiko Kobayashi2. 1. Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6, Shiroishi-ku, Sapporo, Hokkaido, 003-0006, Japan. ken@yacht.ocn.ne.jp. 2. Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6, Shiroishi-ku, Sapporo, Hokkaido, 003-0006, Japan.
Abstract
BACKGROUND: The impact of paranasal sinusitis on the clinical outcome of patients with cancer remains unknown. The aim of this study was to determine whether paranasal sinusitis at the initiation of chemotherapy (SAI) affects the development of infectious complications in children and adolescents with cancer. METHODS: A retrospective cohort analysis of patients aged 0-20 years with cancer who received chemotherapy was performed. SAI was defined as the presence of a fluid level or mucosal swelling or total opacity on sinus computed tomography examination before the initiation of chemotherapy. The primary outcome measures were the incidence of bacteremia, septic shock, and invasive fungal disease (IFD, including proven, probable, and possible cases). RESULTS: SAI was observed in 57 (44%) of 130 enrolled patients. There were no significant differences in age, sex, and disease distribution between the patients with SAI (SAI group) and those without (non-SAI group). There was no significant difference in the 1-year cumulative incidence of bacteremia or septic shock after treatment initiation between the two groups (bacteremia, SAI group 33% vs. non-SAI group 35%, P = 0.53; septic shock, SAI group 4% vs. non-SAI group 4%, P = 0.87). The 1-year cumulative incidence of IFD was higher in the SAI group than in the non-SAI group (22% vs. 6%, P = 0.012). Cumulative incidence analysis after inverse probability of treatment weighting adjustment showed that the SAI group was more likely to develop IFD (HR: 3.5, 95% CI: 1.1-11.2, P = 0.033). CONCLUSIONS: Our findings suggest that patients with SAI may be at higher risk for IFD during chemotherapy.
BACKGROUND: The impact of paranasal sinusitis on the clinical outcome of patients with cancer remains unknown. The aim of this study was to determine whether paranasal sinusitis at the initiation of chemotherapy (SAI) affects the development of infectious complications in children and adolescents with cancer. METHODS: A retrospective cohort analysis of patients aged 0-20 years with cancer who received chemotherapy was performed. SAI was defined as the presence of a fluid level or mucosal swelling or total opacity on sinus computed tomography examination before the initiation of chemotherapy. The primary outcome measures were the incidence of bacteremia, septic shock, and invasive fungal disease (IFD, including proven, probable, and possible cases). RESULTS: SAI was observed in 57 (44%) of 130 enrolled patients. There were no significant differences in age, sex, and disease distribution between the patients with SAI (SAI group) and those without (non-SAI group). There was no significant difference in the 1-year cumulative incidence of bacteremia or septic shock after treatment initiation between the two groups (bacteremia, SAI group 33% vs. non-SAI group 35%, P = 0.53; septic shock, SAI group 4% vs. non-SAI group 4%, P = 0.87). The 1-year cumulative incidence of IFD was higher in the SAI group than in the non-SAI group (22% vs. 6%, P = 0.012). Cumulative incidence analysis after inverse probability of treatment weighting adjustment showed that the SAI group was more likely to develop IFD (HR: 3.5, 95% CI: 1.1-11.2, P = 0.033). CONCLUSIONS: Our findings suggest that patients with SAI may be at higher risk for IFD during chemotherapy.
Authors: Randy A Taplitz; Erin B Kennedy; Eric J Bow; Jennie Crews; Charise Gleason; Douglas K Hawley; Amelia A Langston; Loretta J Nastoupil; Michelle Rajotte; Kenneth V Rolston; Lynne Strasfeld; Christopher R Flowers Journal: J Clin Oncol Date: 2018-09-04 Impact factor: 44.544
Authors: Thomas Lehrnbecher; Paula Robinson; Brian Fisher; Sarah Alexander; Roland A Ammann; Melissa Beauchemin; Fabianne Carlesse; Andreas H Groll; Gabrielle M Haeusler; Maria Santolaya; William J Steinbach; Elio Castagnola; Bonnie L Davis; L Lee Dupuis; Aditya H Gaur; Wim J E Tissing; Theo Zaoutis; Robert Phillips; Lillian Sung Journal: J Clin Oncol Date: 2017-05-01 Impact factor: 44.544
Authors: E Montassier; E Batard; T Gastinne; G Potel; M F de La Cochetière Journal: Eur J Clin Microbiol Infect Dis Date: 2013-01-25 Impact factor: 3.267
Authors: Jake C Valentine; C Orla Morrissey; Mark A Tacey; Danny Liew; Sushrut Patil; Anton Y Peleg; Michelle R Ananda-Rajah Journal: BMC Infect Dis Date: 2019-03-21 Impact factor: 3.090